Investing

Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up

Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds finish their mechanical purchases and attention shifts back to the pipeline.

By David Moadel
Published October 9, 2026, 11:48am ET · 3 min read

Market Movers desk. Editor: David Moadel.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

The white exterior of the Moderna Inc. headquarters building with a large red 'moderna' logo on a white sign above the main entrance. The number '200' is displayed in dark blue on the left wall and in white on the glass revolving door entrance. To the left, a white planter holds green foliage and colorful yellow and purple flowers, while a black slatted trash can sits near the entrance.
The corporate headquarters of Moderna Inc. reflects the company's significant market performance, making it a standout performer in 2026. The biotech firm has seen robust growth, driven by strategic shifts like its oncology pivot. © Maddie Meyer / Getty Images News via Getty Images

Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock trades at $207.80, up 5%, after its addition to the NASDAQ 100 took effect. That entry places a company once valued as a COVID-19 vaccine maker inside one of the most widely tracked growth benchmarks in the market.

Meanwhile, Pfizer (NYSE:PFE) stock is at $28.02, up 0.7%, a far smaller gain than the one in Moderna stock. Additionally, BioNTech (NASDAQ:BNTX) stock is at $94.50, up 3%, landing between the moves in Pfizer stock and Moderna stock.

For a sector gauge, the iShares Biotechnology ETF (NASDAQ:IBB) is up 2%. Broader equities are lagging, with the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) up 0.5%. Biotech names are beating the broad market while Moderna stock is outpacing that group, which ties the move to MRNA stock specifically.

MRNA price target

NASDAQ 100 Entry Forces Fund Buying

Moderna joined the NASDAQ 100 before the opening bell. A large number of funds track that benchmark. They hold its components in proportion, so an addition forces them to buy Moderna shares regardless of what their managers think of the company. That makes the buying a flow event, and it leaves Moderna’s operations, cash generation and pipeline untouched.

Mechanical demand of this kind arrives on a schedule set by the index, whether or not the price looks attractive to the buyers, and those buyers act on index rules alone, so their demand reflects benchmark mechanics with no fresh view on the company. How long that support holds up beyond the rebalancing window is the open question for Moderna stock.

Oncology Data Sets Moderna Apart From Vaccine Peers

Moderna’s personalized cancer therapy met its primary endpoint of recurrence-free survival in a late-stage study in patients with high-risk melanoma. That result strengthened the case for its messenger RNA platform reaching beyond vaccines, and it came before this year’s run in Moderna stock.

Moderna now trades as a growth biotech with an oncology pipeline, a shift from its former identity as a COVID-19 vaccine maker. This repricing is what carried the company into a large-cap growth index in the first place.

Pfizer and BioNTech both emerged from the same vaccine cycle, and Moderna stock stands alone in being rerated this year. The three stocks now move on different drivers despite their shared history.

BioNTech is the closest comparison, since it runs a messenger RNA platform of its own and is likewise pointing it at oncology. However, BioNTech stock is gaining less than Moderna stock, so the shared platform hasn’t translated into a matching move.

What to Watch Next

Once index funds complete their purchases, Moderna stock loses a source of demand tied only to its benchmark status. The test will be whether MRNA shares hold their gains after that rebalancing ends up.

Further results from the oncology pipeline may carry more weight than index flows over time. The focus will be on signs that the pipeline is moving closer to product revenue. Each update has the potential to support or test the rerating that brought Moderna stock this far.

Contact [email protected] for any questions or corrections.

1INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE

Brokerage and Active investing products offered through SoFi Securities LLC, member FINRA(www.finra.org)/SIPC(www.sipc.org).2The probability of a member receiving $3,000 is 0.028%. If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Members must fund their account with a minimum of $50.00 to qualify. The probability percentage is subject to decrease. Members are only eligible for the Stock Award promotion upon opening their first brokerage account; subsequent cash brokerage accounts are ineligible for the promo, including for members with multiple accounts.

3Other fees, such as exchange fees, may apply. Please view our fee disclosure to view a full listing of fees.

4There are limitations with fractional shares to consider before investing. During market hours fractional share orders are transmitted immediately in the order received. There may be system delays from receipt of your order until execution and market conditions may adversely impact execution prices. Outside of market hours orders are received on a not held basis and will be aggregated for each security then executed in the morning trade window of the next business day at market open. Share will be delivered at an average price received for executing the securities through a single batched order. Fractional shares may not be transferred to another firm. Fractional shares will be sold when a transfer or closure request is initiated. Please consider that selling securities is a taxable event.
David Moadel

David Moadel is financial writer specializing in stocks, ETFs, options, precious metals, and Bitcoin. David has written well over 1,000 articles for leading online publications, helping investors understand markets, income strategies, and risk.His work has appeared in The Motley Fool, InvestorPlace, U.S. News & World Report, TipRanks, ValueWalk, Benzinga, Market Realist, TalkMarkets, Finmasters, 24/7 Wall St., and others.With a master’s degree in education, David has taught at the elementary, high school, and college levels. That teaching background shapes his writing style: clear, educational, and practical. David has also built a loyal social-media audience by providing trustworthy financial content on YouTube, X/Twitter, and StockTwits.

All articles →